Quick Answer
Neumora Therapeutics, Inc. reported Cash and Equivalents of $182.53 million for fiscal year 2025.
Neumora Therapeutics, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $182.53M | +28.4% |
| 2024 | $142.15M | -62.0% |
| 2023 | $374.04M | +55.2% |
| 2022 | $240.94M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $129.07M | -53.2% | +3.7% |
| June 30, 2025 | $124.52M | -17.4% | -1.8% |
| March 31, 2025 | $126.86M | -30.6% | -10.8% |
| December 31, 2024 | $142.15M | -62.0% | -48.4% |
| September 30, 2024 | $275.71M | -33.1% | +83.0% |
| June 30, 2024 | $150.68M | -26.2% | -17.6% |
| March 31, 2024 | $182.93M | -13.3% | -51.1% |
| December 31, 2023 | $374.04M | +55.2% | -9.3% |
- Neumora Therapeutics, Inc. showed an increase of +28.4% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2022–2025 period, Neumora Therapeutics, Inc.’s cash and equivalents has declined by 24.2% (from $240.94 million to $182.53 million).
- The most recent figure is from Neumora Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: